Pfizer posts loss of 3.12 billion euros on acquisition

Article Abstract:

Pfizer Inc. posted a $3.59 billion (3.12 billion euros) loss for the 2003 second quarter. The loss was caused mainly by the company's acquisition of Pharmacia Corp. in April 2003.

Sales, profits & dividends, Finance, Company sales and earnings, Company earnings/profit

---

Pfizer nears a deal to acquire Angiosyn, pad eye-drug roster

Article Abstract:

Pfizer Inc. nears an acquisition of Angiosyn Inc., a California biotechnology company working on developing a medication to ward off blindness, for approximately $527 million.

Acquisitions & mergers, Pharmaceutical preparations, Mergers, acquisitions and divestments, Company acquisition/merger

---

Pfizer makes progress on diseases

Article Abstract:

Pfizer Inc.'s scientists have made progress in research on a series of old diseases. Pfizer scientists have made progress on the SARS virus, malaria, and on smallpox.

Science & research, Research, Diseases

Similar abstracts:

• Abstracts: Italian deal brings 5.65 billion euros. Lloyds is near deal to sell bank in New Zealand. HSBC Holdings plans to sell off unit stake
• Abstracts: Pechiney SA. Alcan offers 3.4 billion euros to take over Pechiney. Corus to take its Dutch board to appeals court
• Abstracts: Infineon posts $69.6 million loss due to antitrust-related charge. Infineon loss widened in period
• Abstracts: Camillo Eitzen to acquire Songa. Evergreen Group to expand fleet
• Abstracts: Infineon posts wider net loss despite memory-chip gains. Siemens's earnings jump 29% on 4.6% increase in revenue: engineering firm expects to beat its full-year earnings targets

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.